Richard Law CFA
Stock Analyst at Goldman Sachs
(2.72)
# 2,749
Out of 4,408 analysts
126
Total ratings
39.1%
Success rate
3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintained: Buy | $31 → $35 | $16.30 | +114.72% | 9 | Jun 10, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Hold | $110 | $112.46 | -2.19% | 6 | Jun 10, 2026 | |
| MLYS Mineralys Therapeutics | Maintained: Buy | $42 | $23.92 | +75.59% | 12 | Jun 3, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Hold | $18 | $21.56 | -16.51% | 4 | Jun 1, 2026 | |
| COAG Hemab Therapeutics Holdings | Initiated Coverage: Buy | $36 | $25.08 | +43.54% | 1 | May 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $27 → $23 | $9.88 | +132.79% | 9 | May 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Sell | $11 → $12 | $19.19 | -37.47% | 8 | May 11, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Hold | $34 → $38 | $32.12 | +18.31% | 5 | May 8, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $30 → $34 | $24.18 | +40.61% | 3 | May 7, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Sell | $3 | $2.86 | +4.90% | 7 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $4 | $7.00 | -42.86% | 3 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $35.07 | +91.06% | 5 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $29 → $33 | $25.58 | +29.01% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $120 → $135 | $123.35 | +9.44% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $30 → $33 | $29.63 | +11.37% | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $31 | $12.86 | n/a | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $47 | $31.12 | n/a | 4 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $62 → $63 | $52.61 | n/a | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $37 | $85.61 | n/a | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $76 | $14.92 | n/a | 7 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $18.12 | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $14 | $2.46 | n/a | 3 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 | $7.49 | n/a | 5 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $10 | $3.82 | n/a | 2 | Feb 24, 2023 |
Viridian Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $31 → $35
Current: $16.30
Upside: +114.72%
Protagonist Therapeutics
Jun 10, 2026
Maintained: Hold
Price Target: $110
Current: $112.46
Upside: -2.19%
Mineralys Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: $42
Current: $23.92
Upside: +75.59%
Bicara Therapeutics
Jun 1, 2026
Maintained: Hold
Price Target: $18
Current: $21.56
Upside: -16.51%
Hemab Therapeutics Holdings
May 26, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $25.08
Upside: +43.54%
Olema Pharmaceuticals
May 12, 2026
Maintained: Buy
Price Target: $27 → $23
Current: $9.88
Upside: +132.79%
MoonLake Immunotherapeutics
May 11, 2026
Maintained: Sell
Price Target: $11 → $12
Current: $19.19
Upside: -37.47%
Celldex Therapeutics
May 8, 2026
Maintained: Hold
Price Target: $34 → $38
Current: $32.12
Upside: +18.31%
Arcus Biosciences
May 7, 2026
Maintained: Buy
Price Target: $30 → $34
Current: $24.18
Upside: +40.61%
Rocket Pharmaceuticals
Mar 27, 2026
Maintained: Sell
Price Target: $3
Current: $2.86
Upside: +4.90%
Mar 5, 2026
Maintained: Sell
Price Target: $4
Current: $7.00
Upside: -42.86%
Mar 1, 2026
Maintained: Buy
Price Target: $67
Current: $35.07
Upside: +91.06%
Feb 27, 2026
Maintained: Hold
Price Target: $29 → $33
Current: $25.58
Upside: +29.01%
Nov 18, 2025
Maintained: Buy
Price Target: $120 → $135
Current: $123.35
Upside: +9.44%
Jul 24, 2025
Maintained: Hold
Price Target: $30 → $33
Current: $29.63
Upside: +11.37%
Aug 15, 2023
Maintained: Hold
Price Target: $36 → $31
Current: $12.86
Upside: n/a
Aug 9, 2023
Maintained: Hold
Price Target: $47
Current: $31.12
Upside: n/a
Aug 8, 2023
Maintained: Hold
Price Target: $62 → $63
Current: $52.61
Upside: n/a
Aug 4, 2023
Maintained: Hold
Price Target: $36 → $37
Current: $85.61
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $76
Current: $14.92
Upside: n/a
May 12, 2023
Reiterated: Hold
Price Target: $11
Current: $18.12
Upside: n/a
May 5, 2023
Maintained: Hold
Price Target: $15 → $14
Current: $2.46
Upside: n/a
May 5, 2023
Maintained: Buy
Price Target: $61
Current: $7.49
Upside: n/a
Feb 24, 2023
Upgraded: Hold
Price Target: $10
Current: $3.82
Upside: n/a